February 7, 2023

George Vradenburg – The Future of Alzheimer’s Advocacy Part 2

George Vradenburg – The Future of Alzheimer’s Advocacy Part 2

About This Episode

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?

In this episode of BrainStorm host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative. They explore the implications of the approval of Lecanemab (or Leqembi) worldwide and whether the approval encourages healthy at-risk adults 50 plus to understand their dementia risk profile.

BrainStorm Feed

57

Dr. Rudy Tanzi - How to SHIELD the Brain (part 2)

Join us for part 2 of BrainStorm’s interview with Dr.

LISTEN NOW
56

Dr. Rudy Tanzi – How to SHIELD the Brain (part 1)

Brain health and lifestyle interventions play an important role in longevity.  Dr.

LISTEN NOW
55

George Vradenburg - Advancing the Science of Alzheimer’s Prevention (part 2)

Breakthrough advances in research coupled with health-conscious strategies around brain health continue to bring us closer to the prevention of Alz

LISTEN NOW